Filing Flows › Globe Life (GL) › Stock forecast & fair value
Globe Life (GL) stock forecast and fair value
Globe Life (GL) trades at $157.18. 11 analysts' median price target is $182.00 (+16%), from $161.00 to $215.00. Across 16 valuation methods the middle fair value is $163.31 (+4%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| P/E vs peers | $98.51 | $155.39 | $171.79 | -1% |
| P/E vs peers, weighted | $143.50 | $183.12 | $238.58 | +17% |
| P/E vs peers, matched | $114.28 | $142.19 | $220.84 | -10% |
| P/E vs peers, growth-adjusted | $73.74 | $116.70 | $184.69 | -26% |
| Residual income | $111.92 | $116.24 | $120.81 | -26% |
| P/B vs ROE (insurer peers) | $73.54 | $186.84 | $300.14 | +19% |
| Analysts' price targets | $161.00 | $185.18 | $215.00 | +18% |
| Shareholder yield (dividends + buybacks) | $198.78 | $235.76 | $289.65 | +50% |
| Justified P/B (Gordon growth) | $246.31 | $309.87 | $417.66 | +97% |
| Dividend discount (Gordon) | $23.47 | $29.53 | $39.80 | -81% |
Globe Life's latest quarter
Globe Life, Q3 2026: revenue $1.6B (+6% year over year), operating margin 27.6%, net earnings $361M, operating cash flow $326M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for GL stock?
The median of 11 analysts' 12-month targets is $182.00, +16% from $157.18; the range is $161.00 to $215.00. The average rating is buy.
What is Globe Life's fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between $28.66 and $309.87, with a middle value of $163.31 against a price of $157.18. Each method's assumptions are on the page.
Does Globe Life usually beat earnings estimates?
It beat the consensus EPS estimate in 20% of the quarters on record.
Is GL stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.